280 related articles for article (PubMed ID: 24731928)
1. An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing.
Simen BB; Braverman MS; Abbate I; Aerssens J; Bidet Y; Bouchez O; Gabriel C; Izopet J; Kessler HH; Stelzl E; Di Giallonardo F; Schlapbach R; Radonic A; Paredes R; Recordon-Pinson P; Sakwa J; St John EP; Schmitz-Agheguian GG; Metzner KJ; Däumer MP;
J Virol Methods; 2014 Aug; 204():31-7. PubMed ID: 24731928
[TBL] [Abstract][Full Text] [Related]
2. A Follow-Up of the Multicenter Collaborative Study on HIV-1 Drug Resistance and Tropism Testing Using 454 Ultra Deep Pyrosequencing.
St John EP; Simen BB; Turenchalk GS; Braverman MS; Abbate I; Aerssens J; Bouchez O; Gabriel C; Izopet J; Meixenberger K; Di Giallonardo F; Schlapbach R; Paredes R; Sakwa J; Schmitz-Agheguian GG; Thielen A; Victor M; Metzner KJ; Däumer MP;
PLoS One; 2016; 11(1):e0146687. PubMed ID: 26756901
[TBL] [Abstract][Full Text] [Related]
3. Human immunodeficiency virus type 1 drug resistance testing: Evaluation of a new ultra-deep sequencing-based protocol and comparison with the TRUGENE HIV-1 Genotyping Kit.
Stelzl E; Pröll J; Bizon B; Niklas N; Danzer M; Hackl C; Stabentheiner S; Gabriel C; Kessler HH
J Virol Methods; 2011 Dec; 178(1-2):94-7. PubMed ID: 21907239
[TBL] [Abstract][Full Text] [Related]
4. Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure.
Mohamed S; Penaranda G; Gonzalez D; Camus C; Khiri H; Boulmé R; Sayada C; Philibert P; Olive D; Halfon P
AIDS; 2014 Jun; 28(9):1315-24. PubMed ID: 24698843
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Roche prototype 454 HIV-1 ultradeep sequencing drug resistance assay in a routine diagnostic laboratory.
Garcia-Diaz A; Guerrero-Ramos A; McCormick AL; Macartney M; Conibear T; Johnson MA; Haque T; Webster DP
J Clin Virol; 2013 Oct; 58(2):468-73. PubMed ID: 23954217
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 genotypic resistance testing using the Vela automated next-generation sequencing platform.
Raymond S; Nicot F; Carcenac R; Lefebvre C; Jeanne N; Saune K; Delobel P; Izopet J
J Antimicrob Chemother; 2018 May; 73(5):1152-1157. PubMed ID: 29444253
[TBL] [Abstract][Full Text] [Related]
7. Comparison of HIV-1 drug-resistance genotyping by ultra-deep sequencing and sanger sequencing using clinical samples.
Trabaud MA; Icard V; Ramière C; Tardy JC; Scholtes C; André P
J Med Virol; 2017 Nov; 89(11):1912-1919. PubMed ID: 28590068
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 454 Ultra-Deep Sequencing and Allele-Specific Real-Time PCR with Regard to the Detection of Emerging Drug-Resistant Minor HIV-1 Variants after Antiretroviral Prophylaxis for Vertical Transmission.
Hauser A; Kuecherer C; Kunz A; Dabrowski PW; Radonić A; Nitsche A; Theuring S; Bannert N; Sewangi J; Mbezi P; Dugange F; Harms G; Meixenberger K
PLoS One; 2015; 10(10):e0140809. PubMed ID: 26469189
[TBL] [Abstract][Full Text] [Related]
9. Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.
Dudley DM; Bailey AL; Mehta SH; Hughes AL; Kirk GD; Westergaard RP; O'Connor DH
Retrovirology; 2014 Dec; 11():122. PubMed ID: 25533166
[TBL] [Abstract][Full Text] [Related]
10. 'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing.
Alteri C; Santoro MM; Abbate I; Rozera G; Bruselles A; Bartolini B; Gori C; Forbici F; Orchi N; Tozzi V; Palamara G; Antinori A; Narciso P; Girardi E; Svicher V; Ceccherini-Silberstein F; Capobianchi MR; Perno CF
J Antimicrob Chemother; 2011 Nov; 66(11):2615-23. PubMed ID: 21890537
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Automatic Analysis of Ultradeep Pyrosequencing Raw Data to Determine Percentages of HIV Resistance Mutations in Patients Followed-Up in Hospital.
Bellecave P; Recordon-Pinson P; Fleury H
AIDS Res Hum Retroviruses; 2016 Jan; 32(1):85-92. PubMed ID: 26529549
[TBL] [Abstract][Full Text] [Related]
12. Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.
Geretti AM; Conibear T; Hill A; Johnson JA; Tambuyzer L; Thys K; Vingerhoets J; Van Delft Y;
J Antimicrob Chemother; 2014 Apr; 69(4):1090-7. PubMed ID: 24284781
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity and specificity of the ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI PRISM 3100 genetic analyzer.
Eshleman SH; Crutcher G; Petrauskene O; Kunstman K; Cunningham SP; Trevino C; Davis C; Kennedy J; Fairman J; Foley B; Kop J
J Clin Microbiol; 2005 Feb; 43(2):813-7. PubMed ID: 15695685
[TBL] [Abstract][Full Text] [Related]
14. Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance.
Pattery T; Verlinden Y; De Wolf H; Nauwelaers D; Van Baelen K; Van Houtte M; Mc Kenna P; Villacian J
Intervirology; 2012; 55(2):138-46. PubMed ID: 22286884
[TBL] [Abstract][Full Text] [Related]
15. Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: implications for use in low- and middle-income countries.
Ekici H; Rao SD; Sönnerborg A; Ramprasad VL; Gupta R; Neogi U
J Antimicrob Chemother; 2014 Dec; 69(12):3349-55. PubMed ID: 25085657
[TBL] [Abstract][Full Text] [Related]
16. Detection of low-frequency HIV type 1 reverse transcriptase drug resistance mutations by ultradeep sequencing in naive HIV type 1-infected individuals.
Bellecave P; Recordon-Pinson P; Papuchon J; Vandenhende MA; Reigadas S; Tauzin B; Fleury H
AIDS Res Hum Retroviruses; 2014 Feb; 30(2):170-3. PubMed ID: 23895115
[TBL] [Abstract][Full Text] [Related]
17. Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing.
Todesco E; Rodriguez C; Morand-Joubert L; Mercier-Darty M; Desire N; Wirden M; Girard PM; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2015 May; 70(5):1503-6. PubMed ID: 25614045
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 nucleotide mixture detection in the virco(®)TYPE HIV-1 genotyping assay: a comparison between Sanger sequencing and 454 pyrosequencing.
De Wolf H; Van Marck H; Mostmans W; Thys K; Vandenbroucke I; Van Eygen V; Pattery T; Verhasselt P; Aerssens J
J Virol Methods; 2011 Jul; 175(1):129-32. PubMed ID: 21549149
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants.
Perrier M; Désiré N; Storto A; Todesco E; Rodriguez C; Bertine M; Le Hingrat Q; Visseaux B; Calvez V; Descamps D; Marcelin AG; Charpentier C
PLoS One; 2018; 13(6):e0198334. PubMed ID: 29856864
[TBL] [Abstract][Full Text] [Related]
20. Ultradeep sequencing in the therapeutic management of HIV-1 infection at treatment initiation.
Todesco E; Mercier-Darty M; Jung M; Bottero J; Boyd A; Marcelin AG; Calvez V; Morand-Joubert L
J Antimicrob Chemother; 2015; 70(6):1919-20. PubMed ID: 25637517
[No Abstract] [Full Text] [Related]
[Next] [New Search]
